Every profile is hand-reviewed — leadership, facility, certifications, and sources. Find, compare, and contact real companies instead of wading through scraped data.
319 companies in directory10 countries coveredLatest review: 24 April 2026
Hand-picked companies with the clearest sources and most complete records.
CopenhagenDenmarkTherapeutics
Copenhagen-area neuroscience therapeutics company combining brain-disease R&D, regulated pharmaceutical supply, and global commercial operations.
EspooFinlandDiagnostics
Espoo IVD raw-material headquarters and manufacturing base supplying antibodies, antigens, and assay inputs for diagnostic developers.
DarmstadtGermanyInfrastructure anchor
Darmstadt distribution node connecting German and Baltic operators to cleanroom consumables, bioprocess materials, and laboratory procurement infrastructure.
TartuEstoniaCDMO
Tartu antibody-discovery and recombinant-protein platform now reinforced by a 1,600 m2 cGMP production facility and a broad partner network.
HorsholmDenmarkManufacturing
Hørsholm allergy-immunotherapy headquarters and production-control node anchored in standardized vaccine manufacturing and quality systems.
KvistgaardDenmarkManufacturing
Kvistgaard vaccine-development and manufacturing anchor with commercial biodefense and travel-vaccine platforms operating inside a regulated global network.
10 countries, from the Baltics to Switzerland. Click a country to open its hub with city and category breakdowns.
Region pages drill into cities, categories, and certifications.
Lithuania, Latvia, and Estonia with the strongest Baltic manufacturing, diagnostics, and research operators.
Best starting layer when you want the core Baltic market first.
Use it when you want to move from Lithuania into a broader Baltic comparison.
High-value Polish diagnostics, therapeutic technology, and pharma manufacturing profiles.
Poland bridges Baltic flexibility with larger commercial and manufacturing scale.
Use it when you need the bridge layer between the Baltics and Germany.
Large-scale German therapeutic, manufacturing, and supply profiles for comparative screening.
This is where the directory has its deepest industrial depth and strongest comparison value.
Use it when you need to benchmark Baltic or Polish profiles against larger platforms.
High-trust Swiss manufacturing, CDMO, and therapeutic profiles.
Switzerland provides the premium trust and quality benchmark.
Use it when high-trust supply or CDMO context matters most.
Denmark, Sweden, Finland, and Norway for secondary benchmarking and comparison.
The Nordics help compare the region against mature product and quality systems.
Use it when you need an additional benchmark rather than the core directory layer.
Start from GMP, GLP, ISO 13485, or FDA inspection when the certification matters more than the country or category.
The most active cities and categories are where you’ll find the most comparable companies.
5 / 5 verified
4 / 4 verified
2 / 2 verified
1 / 1 verified
1 / 1 verified
See which infrastructure and supply partners link to other companies in the directory.
Profiles most recently reviewed and updated.
Longer analytical notes that add market, quality, regulatory, and supply-chain context around the directory.
A plain reading of the 2026 EU biotech regulatory package — pharmaceutical reform, the European Health Data Space, the AI Act, and the upcoming EU Biotech Act — and what biotech, pharma, and CDMO companies should do about it.
Open briefWhat the BIO CITY biotechnology city in Vilnius is, how Northway Biotech operates as the 2026 anchor tenant, which capabilities are live at BIO CITY Vilnius today, and how the multi-phase biotech city build-out is progressing — with sources.
Open briefHow biologics manufacturing, drug discovery, and pharmaceutical logistics connect across Germany, Poland, and the Baltics — with named companies and routes you can actually use.
Open briefA practical map of the Baltic clinical research organisation landscape — Biomapas, Cureline Baltic, Inpharmatis, Asper Biogene, BioCC — and why Lithuania, Latvia, and Estonia are a credible nearshore option for EU-regulated clinical trials in 2026.
Open briefHow Swiss and German biologics manufacturing compare in 2026 — Lonza, Bachem, Sandoz, Octapharma, Siegfried on one side and Rentschler, Vetter, IDT Biologika, Wacker Biotech, Merck KGaA on the other — and how to choose the right country for a given programme.
Open briefWhere the European mRNA, vaccine, and immunotherapy supply chain actually sits in 2026 — BioNTech, CureVac, IDT Biologika, AGC Biologics, BioSpring, Bachem, plus the Nordic vaccine layer — and how the pieces fit.
Open briefWhere to look for biologics, fill-finish, small-molecule, and specialised CDMO capacity across Europe in 2026 — 33 CDMOs in the directory across 9 countries, organised by what they actually do and where they sit.
Open briefA practical map of the Polish biotech and pharma landscape in 2026 — Warsaw as pharma and regulatory anchor, Wroclaw as innovation belt, Krakow as discovery cluster, plus CDMO, clinical-research, and supply-chain layers — with 39 operators in the directory.
Open briefWhere to manufacture viral vectors in Europe in 2026 — FinVector, Kuopio Center for Gene and Cell Therapy, 3PBIOVIAN, Fuse Vectors, IDT Biologika — and how the European viral vector CDMO layer is structured.
Open briefA practical map of the Baltic biotech and pharma landscape in 2026 — 74 operators across Lithuania, Latvia, and Estonia, organised by city, category, and what each actually does in the European supply chain.
Open briefA practical map of the German biotech and pharma landscape in 2026 — 57 operators across Heidelberg, Berlin, Mainz, Hamburg, Munich, and smaller sites, organised by what they actually do and how the pieces connect.
Open briefA practical decision guide for sponsors evaluating a European biotech partner in 2026 — CDMO, CRO, discovery services, clinical-stage therapeutics, manufacturing, or logistics — with cross-links to the landscape briefs and directory pages that cover each layer.
Open briefA practical map of the Nordic biotech and pharma landscape in 2026 — 124 operators across Denmark, Sweden, Finland, and Norway, anchored by Novo Nordisk, Genmab, Lundbeck, AstraZeneca Gothenburg, Bavarian Nordic, Orion, and a dense Medicon Valley + Karolinska cluster layer.
Open briefA practical map of the Swiss biotech and pharma landscape in 2026 — 36 operators anchored by Roche and Novartis in Basel, peptide and oligonucleotide API at Bachem, large-scale biologics at Lonza, and Lemanic + Zurich innovation clusters.
Open briefA practical map of the European diagnostics sector in 2026 — 47 operators spanning molecular diagnostics, liquid biopsy, IVD, digital pathology AI, point-of-care, genetic screening, and national laboratory networks across 10 countries.
Open briefA practical map of the European cell and gene therapy landscape in 2026 — CAR-T and TCR-T therapeutics, stem-cell and regenerative ATMPs, tissue engineering, plus the viral-vector CDMO and tools supply chain — across 26 operators in the directory.
Open briefHow European pharmaceutical cold chain and GDP-certified logistics actually work in 2026 — DHL Life Sciences & Healthcare (four German sites), Kuehne+Nagel Healthcare (Germany + Poland), World Courier (Germany + Baltics + Poland), and the Thermo Fisher + Avantor reagent supply layer.
Open briefA practical map of the European antibody + antibody-drug-conjugate + biosimilar therapeutics sector in 2026 — Genmab, ADC Therapeutics, Adcendo, Affimed, Tubulis, Heidelberg Pharma, Sandoz, Mabion, plus a Swedish + Swiss + Polish antibody innovator belt.
Open briefA practical map of the European vaccines sector in 2026 — Bavarian Nordic MVA-BN biodefence, BioNTech and CureVac mRNA, ALK-Abelló allergen immunotherapy, Valneva infectious-disease vaccines, Statens Serum Institut, plus a specialised clinical-stage innovator layer.
Open briefWhere to run European drug discovery services in 2026 — Evotec, Selvita, Charles River Finland, Gubra, Admescope, plus a Swiss + Polish + Nordic tool + platform layer for medicinal chemistry, DMPK, ADMET, and translational research.
Open briefA practical map of the European radiopharmaceutical sector in 2026 — Eckert & Ziegler medical isotopes, 3B Pharmaceuticals peptide radiopharmaceuticals, the Oslo alpha-emitter cluster (Thor Medical, Oncoinvent), Diaprost radioimmunotherapy, and PharmaSynth PET/SPECT precursors.
Open briefA practical map of the European genomics and sequencing sector in 2026 — Estonian Genome Center, CasZyme CRISPR-Cas, Blueprint Genetics NGS diagnostics, CeGaT, Asper Biogene, plus the Baltic + Nordic single-cell and NIPT layer.
Open briefA cross-modality map of European oncology therapeutics in 2026 — 70 operators across antibodies, ADCs, CAR-T + TCR-T cell therapies, mRNA cancer vaccines, alpha-emitter radiopharma, oncolytic viruses, small-molecule discovery, and cancer diagnostics.
Open briefA practical map of the European CNS and neuroscience therapeutics sector in 2026 — Lundbeck (Copenhagen), BioArctic (Stockholm, lecanemab with Eisai), Idorsia (Allschwil, sleep + CNS), Noema Pharma (Basel), Herantis Pharma, Gain Therapeutics, Hoba Therapeutics, plus the discovery + biomarker layer.
Open briefA practical map of the European cardiometabolic therapeutics sector in 2026 — Novo Nordisk (insulin + GLP-1), Zealand Pharma (peptides), AstraZeneca Gothenburg, plus the heart failure + atrial fibrillation + fibrosis + renal therapeutic clusters.
Open briefA practical map of the European AI-enabled drug discovery and computational biology sector in 2026 — generative protein design, AI pathology, computational drug discovery CROs, AI imaging diagnostics, and the operators wiring machine learning into therapeutic pipelines.
Open briefA practical map of the European rare disease and orphan therapeutics sector in 2026 — Sobi, Hansa Biopharma, Ascendis Pharma, Calliditas, Gain Therapeutics, Noema Pharma, Hoba Therapeutics, AB2 Bio, AlgiPharma, plus the Type 1 diabetes precision-immunotherapy and rare-vaccine layers.
Open briefA practical map of the European microbiome and live biotherapeutics sector in 2026 — Aurealis (engineered lactic-acid bacteria), Human Biome Institute (FMT + donor-independent microbial therapeutics), Novonesis (industrial microbial solutions), plus the microbial CDMO + enzyme-tooling layer.
Open briefA practical map of the European anti-infectives and antimicrobial resistance sector in 2026 — Basilea (Cresemba, Zevtera), BioVersys, Biosergen, Modus Therapeutics, AlgiPharma, plus the rapid molecular diagnostics + AMR detection layer.
Open briefA practical map of the European sterile fill-finish CDMO sector in 2026 — Vetter Pharma, IDT Biologika, Bavarian Nordic, Recipharm, FUJIFILM Diosynth, 3P Biovian, plus the Baltic + Polish sterile manufacturing layer.
Open briefA practical map of the European ophthalmology and dermatology therapeutics sector in 2026 — LEO Pharma global dermatology, Arctic Bioscience marine-lipid psoriasis, Aranda Pharma topical androgen-receptor, BioResearch Pharma alopecia + psoriasis, Pharmidea ophthalmic, plus the regenerative skin + tissue-engineering layer.
Open briefUse them when you need to move from an individual company profile into a broader market, compliance, or cross-border execution view.
